Medtronic (NYSE:MDT) said yesterday that it inked a deal to acquire cardiac ablation tech developer Epix Therapeutics, formerly known as Advanced Cardiac Therapeutics, for an undisclosed amount. Santa Clara, Calif.-based Epix’s flagship device is the DiamondTemp catheter-based radiofrequency cardiac ablation system, which won CE Mark approval in the European Union in 2017. The company is engaged […]
These medtech companies raised the most VC last year
Perhaps there’s a ray of hope that venture capital funding is recovering a bit for the medical device industry. VC firms invested more than $2.8 billion in 2017, an increase of more than $647 million from 2016, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and CB Insights. There were a total 229 deals involving […]
ACT touts 1st-in-human trial for RF ablation tech
Advanced Cardiac Therapeutics said yesterday the 1st 12 patients have been treated using its open-irrigated radio frequency ablation technology to treat atrial fibrillation. The treatments were performed in Prague by study principal investigator Dr. Vivek Reddy of Mt. Sinai Hospital, the company said. ACT’s RF tech incorporates a generator with a novel temperature-sensing low-flow catheter […]
Plan for Medtronic-Covidien management structure unveiled | The week in medtech M&A
Abbott buys into electrophysiology with $250m Topera acquisition
Edwards CEO Mussallem announces stock plans | Personnel Moves
First hybrid MRI/PET scanner cleared by FDA | Regulatory Roundup
The FDA announced today that it cleared the Siemens AG (NYSE:SI) Biograph, the first device to perform positron emission tomography scanning and magnetic resonance imaging scanning at the same time.
PET scans allow physicians to see how organs are functioning by injecting radioactive tracers into a patient’s blood stream and MRIs use magnetic fields and radiowaves to create detailed images of organs, soft tissues, bones and other body structures.
Stryker taps ex-J&J exec to lead neurotech and spine group | Personnel moves
Svelte touts six-month outcomes for angioplasty system | Research roundup
Svelte Medical Systems Inc. closed a six-month follow-up analysis for the first clinical trial of its Acrobat angioplasty system.
CEO Mark Pomeranz said the "excellent" results from the Europe and South America-based trial are a "significant milestone" for the New Providence, N.J.-based company.
The company calls the Acrobat device an "all in one" stenting system.
MassDevice Network
@MassDevice
LinkedIn
YouTube